Over four years have passed since British Columbia announced its Biosimilars Initiative. Since then, seven provinces and two territories have followed suit. This means people on originator biologics, for which there are biosimilars, will be (or have already) transitioned to biosimilars in these provinces. Individuals starting a drug for the first time will be prescribed a biosimilar rather than an originator biologic.
Biosimilars are safe, effective, near-identical copies of their biologic originators and are held to the same rigorous standards. However, any treatment changes can be concerning – especially once a person has found a medication that works for them.
We’re conducting research to understand the impact of biosimilar transition policies on people living with different types of inflammatory arthritis. Discover biosimilars research, resources, patient stories and more in Episode 11 of the Arthritis Research Education Series.
Want to support research like this & more?
Change can be hard. Learn about biosimilars and transition policies and find reassurance in research.Watch Episode & Webinar